TY - JOUR T1 - Amyloid-PET in dementia diagnostics: longer survival of amyloid-positive patients JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1255 LP - 1255 VL - 58 IS - supplement 1 AU - Johannes Fostitsch AU - Lars Frings AU - Martin Boeker AU - Sabine Hellwig AU - Tobias Bormann AU - Philipp Meyer Y1 - 2017/05/01 UR - http://jnm.snmjournals.org/content/58/supplement_1/1255.abstract N2 - 1255Objectives: Given the severe outcome of Alzheimer´s disease (AD), β-amyloid (Aβ)-PET is expected to also have a prognostic value besides its diagnostic value. We examined the prognostic value of Aβ-PET in patients that were examined for diagnosis of manifest dementia.Methods: In the present retrospective analysis, we included patients from our clinical register who received a [11C]PIB-PET for diagnosis of manifest dementia between 05/2009 and 06/2016. Vital status information was obtained in 10/2016. The prognostic value of [11C]PIB-PET-findings (dichotomized as Aβ- vs. Aβ+) was assessed by Cox regression model (adjusted for sex and age).Results: 262 patients were included; the vital status of 230 patients could be verified by follow-up. Based on amyloid status patients were allocated to subgroups: Aβ+ group (n= 137; median follow up: 3.7 y / MMSE: 22.4 ± 4.2 / years of education: 13.8 ± 4.0 y) and Aβ- group (n= 93; median follow up: 3.2 y / MMSE: 22.8 ± 4.9 / years of education: 13.1 ± 3.1 y). In both subgroups 15 patients each had died. Patients with an Aβ- scan had a 2.8-times higher risk of dying (p < 0.01). The median time of survival for Aβ- patients was 6.5 y; it was not reached in Aβ+ patients. In the groups of deceased patients, the FDG-PET results were compatible with frontotemporal dementia (FTD) and AD in 11/15 patients each with an Aβ- and Aβ+ scan, respectively.Conclusion: Patients assessed for dementia diagnostics have a shortened life span in general (Ostbye et al., 1999). Our study demonstrates that Aβ-PET allows for additional risk stratification. The somewhat surprising result (better prognosis for Aβ+ patients) is presumably explained by the fact that a significant fraction of Aβ- patients suffer from a disease, which is associated with a worse prognosis than AD (FTD, in particular). ER -